Cybin Insider Trading

Cybin Inc., which operates under the name Helus Pharma, is a clinical-stage pharmaceutical company based in Toronto, Canada, focused on developing treatments for psychiatric and neurological conditions. The company’s lead program, HLP003, is a deuterated psilocybin analog currently in Phase 3 clinical trials for major depressive disorder. Its second clinical-stage asset, HLP004, is a deuterated form of DMT being evaluated in Phase 2 trials for generalized anxiety disorder. At the preclinical stage, the company is developing HLP005, a phenethylamine and tryptamine derivative targeting central nervous system conditions. Cybin has established a strategic partnership with Segal Trials to study HLP003 as an adjunctive treatment for major depressive disorder, and a separate partnership with Osmind focused on mental health treatments. The company operates within the biotechnology sector under the broader healthcare industry.